Search Results
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Ploutarchos Tzoulis in
Google Scholar
PubMed
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
cancer’, ‘pituitary carcinoma’, ‘parathyroid carcinoma’, ‘neuroendocrine tumours and carcinomas’. These keywords were combined using Boolean operators AND/OR. The literature search was executed independently by three investigators (PT, MT and AA). The
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St. Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Lene W Vestermark in
Google Scholar
PubMed
Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Morten Ladekarl in
Google Scholar
PubMed
Search for other papers by Elizaveta Mitkina Tabaksblat in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
3 neuroendocrine tumors (NET G3) or poorly differentiated neuroendocrine carcinomas (NECs) ( WHO 2019 ). The molecular features of HG-GEP NENs are not well characterized, but some recent reports have shed new light on the landscape of somatic
Search for other papers by Wiebke Werner in
Google Scholar
PubMed
Search for other papers by Katharina Detjen in
Google Scholar
PubMed
Search for other papers by Alix Bruneau in
Google Scholar
PubMed
Search for other papers by Isabella Lurje in
Google Scholar
PubMed
Search for other papers by Natalie Nestel in
Google Scholar
PubMed
Search for other papers by Henning Jann in
Google Scholar
PubMed
Search for other papers by Frank Tacke in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine, University Düsseldorf, Düsseldorf, Germany
Search for other papers by Christoph Roderburg in
Google Scholar
PubMed
Search for other papers by Linda Hammerich in
Google Scholar
PubMed
present as well-differentiated NET G3 or poorly differentiated neuroendocrine carcinomas (NEC) ( Nagtegaal et al. 2020 ). Despite the prognostic implications of the WHO classification system with G1 tumors showing a near to normal life expectancy
Search for other papers by Himisha Beltran in
Google Scholar
PubMed
Search for other papers by Francesca Demichelis in
Google Scholar
PubMed
neuroendocrine carcinoma ( Beltran et al. 2011 , Bluemn et al. 2017 , Aggarwal et al. 2018 ). As new drugs enter the clinic for neuroendocrine prostate cancer, patient selection will be critical. Figure 1 Schematic of the lineage plasticity process
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Laura Gerard in
Google Scholar
PubMed
Search for other papers by Céline Patte in
Google Scholar
PubMed
Search for other papers by Laurence Chardon in
Google Scholar
PubMed
Service Central d’Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Léa Payen in
Google Scholar
PubMed
Search for other papers by Marion Allio in
Google Scholar
PubMed
Search for other papers by Claire Marx in
Google Scholar
PubMed
Search for other papers by Hugo Clermidy in
Google Scholar
PubMed
Search for other papers by Alice Durand in
Google Scholar
PubMed
Search for other papers by Patrick Mehlen in
Google Scholar
PubMed
Search for other papers by Julien Bollard in
Google Scholar
PubMed
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Colette Roche in
Google Scholar
PubMed
Search for other papers by Benjamin Gibert in
Google Scholar
PubMed
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
separated in well-differentiated neuroendocrine tumours (NETs, or ‘carcinoid’ for lung NETs) and in poorly differentiated neuroendocrine carcinomas (NECs). Despite chromogranin A (CgA) is the main established tissue and circulating marker for the management
Inserm U1016, CNRS UMR 8104, Institut Cochin, Université Paris Descartes-Université de Paris, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Department of Neurosurgery, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
Search for other papers by Bertrand Baussart in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Hôpital Cochin APHP, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
Lyon 1 University, Villeurbanne, France
Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France
Search for other papers by Gerald Raverot in
Google Scholar
PubMed
Search for other papers by Federico Roncaroli in
Google Scholar
PubMed
neuroendocrine tumour (PitNET) ( Subtype ) Atypical adenoma – – – Carcinoma Carcinoma Carcinoma Metastatic PitNET ( Subtype ) ICD-O code a 8272
Search for other papers by Fritz-Line Vélayoudom-Céphise in
Google Scholar
PubMed
Search for other papers by Pierre Duvillard in
Google Scholar
PubMed
Search for other papers by Lydia Foucan in
Google Scholar
PubMed
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Cecile N Chougnet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by David Malka in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Joël Guigay in
Google Scholar
PubMed
Search for other papers by Diane Goere in
Google Scholar
PubMed
Search for other papers by Thierry Debaere in
Google Scholar
PubMed
Search for other papers by Caroline Caramella in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by David Planchard in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
based on the combination of morphological features and of mitotic count and/or Ki67 index ( Rindi et al . 2010 ): neuroendocrine tumor (NET)/neoplasm G1, NET/neoplasm G2, and neuroendocrine carcinomas (NEC). In this new classification, the grading
Search for other papers by Philipp Melhorn in
Google Scholar
PubMed
Search for other papers by Peter Mazal in
Google Scholar
PubMed
Search for other papers by Ladislaia Wolff in
Google Scholar
PubMed
Search for other papers by Petar Popov in
Google Scholar
PubMed
Search for other papers by Elisabeth Kretschmer-Chott in
Google Scholar
PubMed
Search for other papers by Alexander Haug in
Google Scholar
PubMed
Weill Cornell Medical College, Cornell University, New York, New York, USA
Search for other papers by Marius E Mayerhoefer in
Google Scholar
PubMed
Search for other papers by Markus Raderer in
Google Scholar
PubMed
Search for other papers by Barbara Kiesewetter in
Google Scholar
PubMed
in patients with neuroendocrine carcinoma (NEC) ( Pavel et al. 2020 ), whereas no specific standard has been established for well-differentiated neuroendocrine tumors (NET). Historically, streptozotocin/5-fluorouracil (STZ/5-FU) for pancreatic NETs
The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA
Center for Cancer Engineering, The Ohio State University, Columbus, Ohio, USA
Search for other papers by Aleksander Skardal in
Google Scholar
PubMed
Search for other papers by Hemamylammal Sivakumar in
Google Scholar
PubMed
Search for other papers by Marco A Rodriguez in
Google Scholar
PubMed
Search for other papers by Liudmila V Popova in
Google Scholar
PubMed
Center for Cancer Engineering, The Ohio State University, Columbus, Ohio, USA
Division of Surgical Oncology, The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA
Search for other papers by Priya H Dedhia in
Google Scholar
PubMed
, adrenal, pancreas, parathyroid, and pituitary glands. Specific examples include thyroid cancers, adrenocortical carcinoma (ACC), neuroendocrine tumors (NETs), paraganglioma, and pheochromocytoma ( Belfiore & Perks 2013 ). With incidences of several
Department of Diabetology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Marc Diedisheim in
Google Scholar
PubMed
Department of Gastroenterology and Digestive Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Solène Dermine in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Anne Jouinot in
Google Scholar
PubMed
Search for other papers by Amandine Septier in
Google Scholar
PubMed
Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Sébastien Gaujoux in
Google Scholar
PubMed
Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Bertrand Dousset in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Department of Diabetology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Etienne Larger in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Search for other papers by Raphael Scharfmann in
Google Scholar
PubMed
Department of Pathology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Benoit Terris in
Google Scholar
PubMed
Department of Gastroenterology and Digestive Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Romain Coriat in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
’ recruitment and follow-up Duodenal or pancreatic neuroendocrine tumors or carcinoma were collected between 2001 and 2018 after surgical management. Diagnosis was based on WHO 2017 classification ( Inzani et al. 2018 ). Primary tumors were collected, except